MEDIA ADVISORY, Oct. 9, 2006 (PRIMEZONE) --
What:
James Howard-Tripp, CEO of Labopharm Inc. (DDSS) will preside over
the closing bell to celebrate its listing on the NASDAQ.
Where:
NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio
When:
Tuesday October 10th, 2006 at 4:00 p.m. EDT
Contacts:
Jason Hogan
Investor Relations
416-433-4129
jhogan@labopharm.com
NASDAQ MarketSite:
Stephanie Lowenthal; 646.441.5220
Feed Information:
The closing bell is available from 3:50 p.m. to 4:05 p.m. on uplink IA-6 C-band/transponder 17. The downlink frequency is 4040 Vertical; Audio 6.2-6.8. The feed can also be found on Waterfront fiber 1623. If you have any questions, please contact Stephanie Lowenthal at (646) 441-5220.
Photos:
To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.
About Labopharm Inc. (DDSS):
Labopharm Inc. (TSX:DDS) (Nasdaq:DDSS) is an international, specialty pharmaceutical company focused on the development of drugs incorporating Contramid(r), the Company's proprietary advanced controlled-release technology. Labopharm's lead in-house product, a once-daily formulation of the analgesic tramadol, has received regulatory approval in 22 European countries and commercial launch of the product across Europe is underway. In the U.S., the Company has received an Approvable Letter from the FDA and is working with its marketing partner for the U.S., Purdue Pharma, to prepare for the launch of the product upon final approval. The Company's pipeline includes a combination of in-house and partnered programs with products both in clinical trials and in preclinical development. For more information, please visit www.labopharm.com.